Open Access<p>Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2–3 After Progression of Second-Line or Later-Line Treatment</p>
Author(s) -
Xian-Jin Xie,
Fei Wang,
Xiaoyan Lin,
Yinyin Qin,
Zhanhong Xie,
Jiexia Zhang,
Ming Ouyang,
Chengzhi Zhou
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s278068
Subject(s) - medicine , regimen , adverse effect , lung cancer , chemotherapy , oncology , progression free survival , gastroenterology
The study aimed to analyze the efficacy and safety of combination regimen of anlotinib and S-1 for Chinese patients with EGFR mutation-negative advanced squamous cell lung cancer (SqCLC) with poor performance status (PS,2-3) after progression of second-line or later-line chemotherapy.